Cereno Scientific (XSAT:CRNO B) reports first patient enrolled in Phase II study in PAH with drug candidate CS1 and update timeline for top-line results to Q1 2023
Cereno Scientific (XSAT: CRNO B) today reported that the first patient has been enrolled in the Phase II study in...